Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

Recent & Breaking News (TSXV:RP)

RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial

Canada NewsWire July 21, 2015

RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial

Canada NewsWire July 21, 2015

RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis

Canada NewsWire June 30, 2015

RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement

Canada NewsWire June 26, 2015

RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC

Canada NewsWire June 5, 2015

RepliCel Life Sciences Announces Brokered Private Placement

Canada NewsWire June 1, 2015

RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference

Canada NewsWire May 21, 2015

RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum

Canada NewsWire May 7, 2015

Tech Roundup: RepliCel (V.RP) grows, SoMedia (V.VID) profits, WiLAN (WILN) flounders

Gaalen Engen May 1, 2015

SoMedia Networks (V.VID) reports record sales growth of 125% in 2014

Stockhouse Editorial May 1, 2015

RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results

Canada NewsWire April 29, 2015

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis

Canada NewsWire April 15, 2015

RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates

Canada NewsWire April 7, 2015

RepliCel Life Sciences Applies to Extend Warrant Expiry Dates

Canada NewsWire April 2, 2015

Pete's Picks: Noront (V.NOT) up 40% as Franco-Nevada (T.FNV) enters Ring of Fire

Peter Kennedy March 23, 2015

RepliCel Life Sciences (V.RP) hits lucrative bio-med trifecta with innovative tech

Gaalen Engen March 16, 2015

RepliCel Life Sciences in Japan for Key Industry Meetings

Canada NewsWire March 12, 2015

Canada and Japan Leading Innovation in Regenerative Medicine; Two Nations, Different Strategies, One Goal: Addressing Incurable Medical Conditions

GlobeNewswire March 10, 2015

RepliCel Submits Clinical Trial Application for its Dermatological Product

Canada NewsWire February 23, 2015

RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC

Canada NewsWire January 20, 2015